Cargando…

Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis

Numerous studies have investigated the prognostic values of MYC and/or BCL2 protein overexpression in diffuse large B-cell lymphoma (DLBCL). However, the results still demonstrate discrepancies among different studies. We aimed to do a systematic review and meta-analysis on the relationships between...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Lu, Li, Yanyan, Que, Ximei, Gao, Xue, Gao, Qian, Yu, Mingxing, Ma, Kaili, Xi, Yanfeng, Wang, Tong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908914/ https://www.ncbi.nlm.nih.gov/pubmed/29674626 http://dx.doi.org/10.1038/s41598-018-24631-5

Ejemplares similares

P1216: ZANUBRUTINIB PLUS R-CHOP(RI-CHOP) AS THE TREATMENT FOR DOUBLE EXPRESSION OF MYC/BCL2 IN PATIENTS WITH DIFFUSED LARGE B-CELL LYMPHOMA
por: Ren, K., et al.
Publicado: (2022)

Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression
por: Okada, Yosuke, et al.
Publicado: (2021)

MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients
por: Wang, Yanjie, et al.
Publicado: (2023)

Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers
por: Pedersen, Mette Ølgod, et al.
Publicado: (2017)

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

Overexpression of MYC and BCL2 Predicts Poor Prognosis in Patients with Extranodal NK/T-cell Lymphoma, Nasal Type
por: Wang, Jing-hua, et al.
Publicado: (2017)

Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma
por: Choi, Soyeon, et al.
Publicado: (2022)

Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B-Cell Lymphoma with MYC-Rearrangement, and Diffuse Large B-Cell Lymphoma with MYC-Cluster Amplification
por: Miyaoka, Masashi, et al.
Publicado: (2022)

Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin
por: Wawire, Jonathan, et al.
Publicado: (2019)

Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP
por: Peroja, Pekka, et al.
Publicado: (2018)

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP
por: Qin, Yan, et al.
Publicado: (2022)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

Correlation Between C-MYC, BCL-2, and BCL-6 Protein Expression and Gene Translocation as Biomarkers in Diagnosis and Prognosis of Diffuse Large B-cell Lymphoma
por: Zhang, YunXiang, et al.
Publicado: (2019)

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma
por: Ye, Qing, et al.
Publicado: (2015)

Immunohistochemistry for c‐myc and bcl‐2 overexpression improves risk stratification in primary central nervous system lymphoma
por: Hatzl, Stefan, et al.
Publicado: (2020)

Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas
por: Tariq, Ayesha, et al.
Publicado: (2018)

Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma
por: de Jong, Mathilde Rikje Willemijn, et al.
Publicado: (2019)

MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
por: Yan, Li-Xu, et al.
Publicado: (2014)

Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study
por: Ma, Qianwen, et al.
Publicado: (2019)

MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B‐cell lymphoma
por: Kawamoto, Keisuke, et al.
Publicado: (2016)

R-split-EPOCH plus high dose methotrexate in untreated diffuse large B cell lymphoma with MYC rearrangement or double expression of MYC and BCL-2
por: Sun, Peng, et al.
Publicado: (2021)

Correction: MYC Expression in Concert With BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
por: Yan, Li-Xu, et al.
Publicado: (2018)

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial
por: Johnson, Peter W. M., et al.
Publicado: (2023)

MYC overexpression with its prognostic and clinicopathological significance in breast cancer
por: Qu, Jingkun, et al.
Publicado: (2017)

MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma
por: Lu, Ting-Xun, et al.
Publicado: (2015)

Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy
por: Guo, Wei, et al.
Publicado: (2015)

Upregulation of fatty acid synthase in MYC and BCL-2 double-expressor lymphoma
por: Zhong, Xing, et al.
Publicado: (2021)

A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma
por: Bosch, Mark, et al.
Publicado: (2018)

c‐MYC and p53 expression highlight starry‐sky pattern as a favourable prognostic feature in R‐CHOP‐treated diffuse large B‐cell lymphoma
por: Bouroumeau, Antonin, et al.
Publicado: (2021)

Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma
por: Wang, Jing, et al.
Publicado: (2015)

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
por: Cho, Kyoung Min, et al.
Publicado: (2019)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms
por: Wang, Liang, et al.
Publicado: (2021)

Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients
por: Huang, Ying, et al.
Publicado: (2012)

Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma
por: Hu, Xin, et al.
Publicado: (2017)

C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases
por: Salam, Dayang Sharyati Datu Abdul, et al.
Publicado: (2020)

TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment
por: Singh, Aditi, et al.
Publicado: (2022)

Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma
por: Liu, Xiaoqian, et al.
Publicado: (2022)

BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase
por: Zou, Dehui, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_s7r9avmvua3hnt984q3tagk1rt